{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:49:16Z","timestamp":1776124156727,"version":"3.50.1"},"reference-count":9,"publisher":"American Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"name":"Philanthropic foundations"},{"name":"Government of Quebec"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>The cardiovascular benefits of low-dose colchicine have been demonstrated in patients with coronary disease. Its effects were evaluated in this prespecified analysis in patients with type 2 diabetes (T2D) from the Colchicine Cardiovascular Outcomes Trial (COLCOT).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>COLCOT was a randomized, double-blinded trial of colchicine, 0.5 mg daily, versus placebo initiated within 30 days after a myocardial infarction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>There were 959 patients with T2D enrolled and monitored for a median of 22.6 months. A primary end point event occurred in 8.7% of patients in the colchicine group and in 13.1% in the placebo group (hazard ratio 0.65; 95% CI 0.44\u20130.96; P = 0.03). Nausea was reported in 2.7% and 0.8% in the study groups (P = 0.03), and pneumonia occurred in 2.4% and 0.4% (P = 0.008).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Among patients with T2D and a recent myocardial infarction, colchicine, 0.5 mg daily, leads to a large reduction of cardiovascular events. These results support the conduct of the COLCOT-T2D trial in primary prevention.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc23-1825","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T20:15:57Z","timestamp":1704485757000},"page":"467-470","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":51,"title":["Low-Dose Colchicine in Patients With Type 2 Diabetes and Recent Myocardial Infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)"],"prefix":"10.2337","volume":"47","author":[{"given":"Fran\u00e7ois","family":"Roubille","sequence":"first","affiliation":[{"name":"1PhyMedExp, Universit\u00e9 de Montpellier, INSERM, CNRS, Cardiology Department, University Hospital of Montpellier, Montpellier, France"}]},{"given":"Nadia","family":"Bouabdallaoui","sequence":"additional","affiliation":[{"name":"2Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}]},{"given":"Simon","family":"Kouz","sequence":"additional","affiliation":[{"name":"3Centre Hospitalier R\u00e9gional de Lanaudi\u00e8re, Joliette, Quebec, Canada"}]},{"given":"David D.","family":"Waters","sequence":"additional","affiliation":[{"name":"4San Francisco General Hospital, San Francisco, CA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2181-9579","authenticated-orcid":false,"given":"Rafael","family":"Diaz","sequence":"additional","affiliation":[{"name":"5Estudios Cl\u00ednicos Latinoam\u00e9rica, Rosario, Argentina"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[{"name":"6Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO) Research Center, Heart Care Foundation, Florence, Italy"}]},{"given":"Fausto J.","family":"Pinto","sequence":"additional","affiliation":[{"name":"7Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal"}]},{"given":"Jean C.","family":"Gr\u00e9goire","sequence":"additional","affiliation":[{"name":"2Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}]},{"given":"Habib","family":"Gamra","sequence":"additional","affiliation":[{"name":"8Fattouma Bourguiba University Hospital, Monastir, Tunisia"}]},{"given":"Ghassan S.","family":"Kiwan","sequence":"additional","affiliation":[{"name":"9Bellevue Medical Center, Beirut, Lebanon"}]},{"given":"Colin","family":"Berry","sequence":"additional","affiliation":[{"name":"10Institute of Cardiovascular and Medical Sciences, University of Glasgow, and National Health Service Greater Glasgow and Clyde, Glasgow, U.K."}]},{"given":"Jos\u00e9","family":"L\u00f3pez-Send\u00f3n","sequence":"additional","affiliation":[{"name":"11Centro de Investigaci\u00f3n Biom\u00e9dica en Red\u2013Enfermedades Cardiovasculares, Madrid, Spain"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[{"name":"12Deutsches Herzzentrum Munchen, Technische Universitat Munchen, and DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany"},{"name":"13Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany"}]},{"given":"Laurent","family":"Delorme","sequence":"additional","affiliation":[{"name":"14Clinique du Pont de Chaume, Montauban, France"}]},{"given":"Meyer","family":"Elbaz","sequence":"additional","affiliation":[{"name":"15Cardiology Department, Rangueil University Hospital, Toulouse, France"}]},{"given":"Pierre","family":"Coste","sequence":"additional","affiliation":[{"name":"16H\u00f4pital Cardiologique, Universit\u00e9 de Bordeaux, Bordeaux, France"}]},{"given":"Myl\u00e8ne","family":"Provencher","sequence":"additional","affiliation":[{"name":"17Montreal Health Innovations Coordinating Center, Montreal, Quebec, Canada"}]},{"given":"Zohar","family":"Bassevitch","sequence":"additional","affiliation":[{"name":"17Montreal Health Innovations Coordinating Center, Montreal, Quebec, Canada"}]},{"given":"Lucie","family":"Blondeau","sequence":"additional","affiliation":[{"name":"17Montreal Health Innovations Coordinating Center, Montreal, Quebec, Canada"}]},{"given":"Philippe L.","family":"L\u2019Allier","sequence":"additional","affiliation":[{"name":"2Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}]},{"given":"Marie-Claude","family":"Guertin","sequence":"additional","affiliation":[{"name":"17Montreal Health Innovations Coordinating Center, Montreal, Quebec, Canada"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8200-8983","authenticated-orcid":false,"given":"Jean-Claude","family":"Tardif","sequence":"additional","affiliation":[{"name":"2Montreal Heart Institute, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}]}],"member":"1167","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"2024022320171774800_B1","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.2174\/13816128113199990351","article-title":"Emerging anti-inflammatory therapies for atherosclerosis","volume":"19","author":"Roubille","year":"2013","journal-title":"Curr Pharm Des"},{"key":"2024022320171774800_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.athplu.2021.08.008","article-title":"Colchicine reduces atherosclerotic plaque vulnerability in rabbits","volume":"45","author":"Roubille","year":"2021","journal-title":"Atheroscler Plus"},{"key":"2024022320171774800_B3","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2024022320171774800_B4","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2024022320171774800_B5","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2024022320171774800_B6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jacc.2006.09.046","article-title":"Coronary heart disease in patients with diabetes: part I: recent advances in prevention and noninvasive management","volume":"49","author":"Berry","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2024022320171774800_B7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nri2925","article-title":"Type 2 diabetes as an inflammatory disease","volume":"11","author":"Donath","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"2024022320171774800_B8","doi-asserted-by":"crossref","first-page":"e001206","DOI":"10.1161\/JAHA.112.001206","article-title":"Trends in clinical, demographic, and biochemical characteristics of patients with acute myocardial infarction from 2003 to 2008: a report from the American Heart Association Get With the Guidelines Coronary Artery Disease program","volume":"1","author":"Boyer","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"2024022320171774800_B9","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1161\/01.CIR.98.23.2513","article-title":"Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) trial","volume":"98","author":"Goldberg","year":"1998","journal-title":"Circulation"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/3\/467\/748508\/dc231825.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/3\/467\/748508\/dc231825.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T20:17:35Z","timestamp":1708719455000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/47\/3\/467\/154052\/Low-Dose-Colchicine-in-Patients-With-Type-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,5]]},"published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-1825","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]}}}